Search

Pacific Biosciences of California Inc

Закрыт

СекторЗдравоохранение

1.29 -11.03

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

1.27

Макс.

1.46

Ключевые показатели

By Trading Economics

Доход

32M

-8.3M

Продажи

-7.5M

37M

Прибыль на акцию

-0.12

Рентабельность продаж

-22.258

Сотрудники

485

EBITDA

33M

-5.8M

Рекомендации

By TipRanks

Рекомендации

Нейтрально

Прогноз на 12 месяцев

+65.28% upside

Дивиденды

By Acuity

Следующий отчет о доходах

5 авг. 2026 г.

Рыночная статистика

By TradingEconomics

Рыночная капитализация

-40M

441M

Предыдущая цена открытия

12.32

Предыдущая цена закрытия

1.29

Новостные настроения

By Acuity

34%

66%

130 / 340 Рейтинг в Healthcare

Pacific Biosciences of California Inc График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

4 авг. 2026 г., 21:36 UTC

Pacific Biosciences of California remained roughly flat after market hours. Broader market gains were driven by a decline in crude oil prices.

3 авг. 2026 г., 23:36 UTC

Pacific Biosciences of California Inc. shares are roughly flat after-market, remaining near the lower end of their one-month trading range.

31 июл. 2026 г., 19:46 UTC

News
Correlated Moves

Pacific Biosciences of California is trading lower amid a report citing annual sales declines and cash burn concerns impacting its growth outlook.

29 июл. 2026 г., 16:06 UTC

Correlated Moves

Pacific Biosciences of California Inc shares are lower today, reflecting broader market pressure on small-cap equities and a notable decline in correlated assets.

28 июл. 2026 г., 16:12 UTC

Pacific Biosciences is trading higher, rebounding from earlier losses despite broader market caution following declines in the Nikkei 225 Index.

27 июл. 2026 г., 19:06 UTC

Pacific Biosciences is trading higher as the broader market rises, supported by a notable decline in crude oil prices that has eased geopolitical tensions.

24 июл. 2026 г., 22:31 UTC

Pacific Biosciences shares are higher in after-market trading. No specific company news was identified to explain this movement.

22 июл. 2026 г., 18:01 UTC

Correlated Moves

Pacific Biosciences of California shares are lower amid broader market pressures and rising crude oil prices, trading below its 20-day moving average.

21 июл. 2026 г., 13:01 UTC

Pacific Biosciences is rallying in pre-market trading, continuing its upward trend since Monday's close after three sessions of declines. No specific news was identified.

20 июл. 2026 г., 23:01 UTC

Shares of Pacific Biosciences of California are higher in after-market hours, marking a peak cumulative return since Monday's close amid broader market volatility.

Сравнение c конкурентами

Изменение цены

Pacific Biosciences of California Inc Прогноз

Целевая цена

By TipRanks

65.28% рост

Прогноз на 12 месяцев

Средняя 2.38 USD  65.28%

Максимум 3 USD

Минимум 1.5 USD

Основано на мнении 4 аналитиков Wall Street, спрогнозировавших целевые цены для Pacific Biosciences of California Inc на следующие 12 месяцев – Данные за последние 3 месяца.

Консенсус по рейтингу

By TipRanks

Нейтрально

4 ratings

2

Покупка

1

Удержание

1

Продажа

Настроения

By Acuity

130 / 340Рейтинг в Здравоохранение

Новостные настроения

Свидетельства восходящего тренда

Волатильность

Ниже среднего

Объем новостей (RCV)

Выше среднего

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

$

О компании Pacific Biosciences of California Inc

Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing solution to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) technology; long-red sequencing; and various reagent kits designed for specific workflow, such as preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. In addition, it provides revio system + sequel systems which conduct, monitor, and analyze single-molecule biochemical reactions in real time; SBB short-read sequencing; onso instrument conducts, monitors, and analyzes SBB biochemical reactions; and SBB consumable, including flow cells, clustering, and sequencing reagent kits. The company serves academic and governmental research institutions; commercial testing and service laboratories; genome centers; public health labs, hospitals and clinical research institutes, and contract research organizations; pharmaceutical companies; and agricultural companies. It markets its products through a sales force and distribution partners in Asia, Australia, Europe, the Middle East, Africa, and Latin America. It has a development and commercialization agreement with Invitae Corporation; and a collaboration with Radboud University Medical to explore genetic causes of rare and genetic diseases. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.
help-icon Live chat